Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder

Explore the efficacy of methylphenidate hydrochloride controlled-release tablets add-on pharmacotherapy on clinical symptomatology and cognitive functioning in a sample of patients with obsessive-compulsive disorder (OCD) receiving fluvoxamine maleate. To test the hypothesis that methylphenidate hydrochloride controlled-release tablets augmentation of fluvoxamine treatment is well tolerated and may be proposed as an effective therapeutic strategy to improve outcome in OCD.

Inclusion Criteria:

• Informed consent
• Met DSM-V criteria
• Y-BOCS ≥ 16
• Course of illness ≥ 1year
• Age range between 18~40 years old
• Junior high school education level above

Exclusion Criteria:

• Any other psychiatric axis-I or axis-II disorders
• History of epileptic seizures or any other neurological disorder
• Any other clinically relevant abnormalities in their medical history or laboratory examinations; alcohol or drug abuser